# Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

> **NCT06193928** · — · RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Alagille Syndrome
- Progressive Familial Intrahepatic Cholestasis

## Interventions

- **DRUG:** Livmarli
- **DRUG:** Livmarli

## Key facts

- **NCT ID:** NCT06193928
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2028-09-20
- **Final completion:** 2030-09-20
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06193928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06193928, "Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06193928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*